Randomized Phase II Trial of Parsatuzumab (Anti-Egfl7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First-Line Nonsquamous Non-Small Cell Lung Cancer
The Oncologist（2018）
关键词
Bevacizumab
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要